Vince & Associates Clinical Research Opens Dedicated Neuropsychiatric Research Center
Vince & Associates Clinical Research announces the opening of their new, dedicated Neuropsychiatric Research Center in Overland Park, KS. This research facility supports the needs of the pharmaceutical and biotechnology sectors by providing effective study recruitment, medical management and oversight in study volunteers across a range of neuropsychiatric disorders including both acute and chronic schizophrenia.
“While Vince and Associates has been conducting clinical trials in schizophrenia over the past decade, this dedicated unit will allow us to better serve the needs of both study volunteers and our biopharmaceutical clients,” said Dr. Brad Vince, President and Medical Director.
Debra Kelsh, MD, a Board-Certified Psychiatrist and an Investigator in over 300 clinical trials, will serve as Medical Director of the new Neuropsychiatric Research Center. “The safety and security of our study volunteers was highly emphasized during the design of the unit,” said Dr. Kelsh.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
